Ellipses Pharma to Present Clinical Updates at Leading US Breast and Blood Cancer Conferences – November 21, 2022

LONDON–(BUSINESS WIRE)– Ellipse Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, is pleased to announce that it will provide clinical updates on two of its… Assets will be presented December 6-10, 2022 in San Antonio, Texas and at the 64thth American Society of Hematology (ASH) Annual Meeting and Exhibition December 10-13, 2022 in New Orleans, Louisiana.

A “trial in progress” poster will be presented at SABCS, describing the design of a phase 1/2 study with Vosilasarm (EP0062). EP0062 is a selective androgen receptor modulator currently in development for the treatment of AR+/HER-/ER+ advanced breast cancer.

Preliminary results from Ellipses on the dose escalation portion of the Phase 1/2a first-in-human trial of EP0042 in patients with acute myeloid leukemia (AML) will be presented at ASH. EP0042 is a dual FLT3 and Aurora kinase inhibitor. The study examines the use of EP0042 both as a monotherapy and in combination with existing therapies.

dr Rajan Jethwa, CEO of Ellipses Pharma said:
“Ellipses is committed to rapidly developing novel cancer treatments and bringing them to patients. The presentation of the design of Ellipses’ first study of EP0062 and the preliminary results of study EP0042 at two of the world’s leading oncology conferences took a significant step towards this goal. We are proud of the work our dedicated team has done to conduct these studies and bring to light such potentially exciting data.”

Professor Sir Christopher Evans, Chairman of Ellipses Pharma said:
“The presentation of these two posters is a testament to the potential of the promising assets in Ellipses’ pipeline and demonstrates the progress we have made toward our goal of accelerating the development of much-needed cancer treatments.”
















SABCS: vosilasarm/EP0062

title

A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral selective androgen receptor modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer

author(s)

Elgene Lim, Hendrik-Tobias Arkenau, Sue Brook, Geoff Fisher, Andrew Mazur, and Carlo Palmieri

Abstract number / code

OT1-02-02

Date and Time

Tuesday, December 6, 2022; 5:00 p.m. – 6:15 p.m

Session Name / Category

Trial in progress session

location

Henry B. González Convention, San Antonio, Texas

ASH: EP0042

title

EP0042, a dual FLT3 and aurora kinase inhibitor: preliminary results from an ongoing phase 1/2a first-in-human (FIH) study in patients with relapsed/refractory acute myeloid leukemia (AML)

moderator

David Taussig

Abstract number / code

2768

Date and Time

Sunday 11 December 2022; 18:00 – 20:00

Session Name / Category

616. Acute myeloid leukemias: investigational therapies, excluding transplantation and cellular immunotherapies: poster II

location

Ernest N. Morial Convention Center, New Orleans, Louisiana

END

About Ellipses Pharma Limited
Ellipses Pharma is a London-based global drug development company focused on accelerating the development of cancer drugs and treatments through an innovative drug development model that combines unbiased verification to de-risk initial asset selection with an uninterrupted flow of funding to accelerate time commitment Minimize Advancing leading products through clinical trials and reaching patients.

Visit ellipses.life for more information

View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005100/en/

Source